Design, synthesis, and biological study of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia

References

• Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389–1400. doi:10.1038/nm.338824202392
   PubMed Web of Science ®Google Scholar
• Oronsky B, Ma P, Reid TR, et al. Navigating the “no man’s land” of TKI-failed EGFR-mutated non-small cell lung cancer (NSCLC): a review. Neoplasia. 2018;20(1):92–98. doi:10.1016/j.neo.2017.11.00129227909
   PubMed Web of Science ®Google Scholar
• Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80. doi:10.1016/j.ejca.2017.07.01628787661
   PubMed Web of Science ®Google Scholar
• Cortez AJ, Tudrej P, Kujawa KA, et al. Advances in ovarian cancer therapy. Cancer Chemoth Pharm. 2018;81(1):17–38. doi:10.1007/s00280-017-3501-8
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Sakurai H, Kogashiwa Y, et al. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer. Head Neck. 2017;39(3):476–485. doi:10.1002/hed.2462627880014
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393–410. doi:10.1038/nrc306421606941
   PubMed Web of Science ®Google Scholar
• Wang T, Niki T, Goto A, et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway. Cancer Sci. 2007;98(4):506–511. doi:10.1111/j.1349-7006.2007.00428.x17425591
   PubMed Web of Science ®Google Scholar
• Nishi H, Nishi KH, Johnson AC. Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res. 2002;62(3):827–834.11830539
   PubMed Web of Science ®Google Scholar
• Rawluk J, Waller CF. Gefitinib. Recent Results Cancer Res. 2018;211:235–246. doi:10.1007/978-3-319-91442-8_1630069771
   PubMedGoogle Scholar
• Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics. 2010;28(1):75–92. doi:10.2165/10482880-000000000-0000020014878
   PubMed Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426–1447. doi:10.1016/j.clinthera.2008.08.00818803986
   PubMed Web of Science ®Google Scholar
• Greig SL. Osimertinib: first global approval. Drugs. 2016;76(2):263–273. doi:10.1007/s40265-015-0533-426729184
   PubMed Web of Science ®Google Scholar
• Wack LJ, Monnich D, Yaromina A, et al. Correlation of FMISO simulations with pimonidazole-stained tumor xenografts: a question of O2 consumption? Med Physics. 2016;43(7):4113. doi:10.1118/1.4951728
   PubMed Web of Science ®Google Scholar
• Hassan Metwally MA, Jansen JA, Overgaard J. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial. Clin Oncol. 2015;27(3):168–175. doi:10.1016/j.clon.2014.11.024
   Web of Science ®Google Scholar
• Wei H, Li D, Yang X, et al. Design and synthesis of vandetanib derivatives containing nitroimidazole groups as tyrosine kinase inhibitors in normoxia and hypoxia. Molecules. 2016;21:12. doi:10.3390/molecules21121693
   Web of Science ®Google Scholar
• Cheng W, Yuan Y, Qiu N, et al. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. Bioorg Med Chem. 2014;22(24):6796–6805. doi:10.1016/j.bmc.2014.10.03825468044
   PubMed Web of Science ®Google Scholar
• Cheng W, Zhu S, Ma X, et al. Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia. Eur J Med Chem. 2015;89:826–834. doi:10.1016/j.ejmech.2014.11.01025462282
   PubMed Web of Science ®Google Scholar
• Duan J, Jiao H, Kaizerman J, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008;51:2412–2420. doi:10.1021/jm701028q18257544
   PubMed Web of Science ®Google Scholar
• Nepali K, Lee H, Liou J. Nitro-group-containing drugs. J Med Chem. 2019;62:2851–2893. doi:10.1021/acs.jmedchem.8b0014730295477
   PubMed Web of Science ®Google Scholar
• Cheng W, Zhou J, Tian X, et al. Development of the third generation EGFR tyrosine kinase inhibitors for anticancer therapy. Curr Med Chem. 2016;23:3343–3359.27160532
   PubMed Web of Science ®Google Scholar
• Wang C, Gao H, Dong J, et al. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors. Curr Med Chem. 2014;21(11):1336–1350.24251571
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Hisano H, Nishikawa Y, et al. Targeting and treatment of tumor hypoxia by newly designed prodrug possessing high permeability in solid tumors. Mol Pharm. 2016;13(7):2283–2289. doi:10.1021/acs.molpharmaceut.6b0001127187083
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64(18):6652–6659. doi:10.1158/0008-5472.CAN-04-116815374980
   PubMed Web of Science ®Google Scholar
• Frearson PM, Stern ES. Some new analogues of pethidine. Part III. 1-aryloxy-alkylnorpethidines, and close analogues. J Chem Soc. 1958:3065–3067.
   Web of Science ®Google Scholar
• Liu H, Ji M, Luo XM, et al. New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: design, synthesis, biological assay, and 3D-QSAR analysis. J Med Chem. 2002;45(14):2953–2969. doi:10.1021/jm010574u12086482
   PubMed Web of Science ®Google Scholar
• Ple PA, Green TP, Hennequin LF, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem. 2004;47(4):871–887. doi:10.1021/jm030317k14761189
   PubMed Web of Science ®Google Scholar
• Marzaro G, Guiotto A, Pastorini G, et al. A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines. Tetrahedron. 2010;66(4):962–968. doi:10.1016/j.tet.2009.11.091
   Web of Science ®Google Scholar
• Lueth A, Lowe W. A novel synthesis of EGFR-tyrosine-kinase inhibitors with 4-(indol-3-yl)quinazoline structure. J Heterocyclic Chem. 2008;45(3):703–708. doi:10.1002/jhet.5570450311
   Web of Science ®Google Scholar
• Zhou W, Liu XF, Tu ZC, et al. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant. J Med Chem. 2013;56(20):7821–7837. doi:10.1021/jm401045n24053674
   PubMed Web of Science ®Google Scholar